Blog

The Wall Street Journal 2013-07-26 The Wall Street Journal today published a front page story on the Department of Justice investigation into fraud in physician-owned distributorships of medical devices. Some instances of this

Pharmalot.com, Pharmaceutical Industry News 2013-07-11 In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly

The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia

The American Law Journal 2013-06-16 Attorney Stephen Sheller sparred with pharmaceutical defense attorney Hope Freiwald of Dechert law firm on the television program The American Law Journal. The attorneys, joined by Pharmalot author

2013-06-25 In a case involving a Philadelphia company, a divided U.S. Supreme Court ruled Monday that federal pharmaceutical laws preempt a person’s ability to sue in state court alleging that a generic drug

2013-05-17  The law firm of Sheller, P.C. announces the selection of six attorneys as Pennsylvania SuperLawyers® and one as Pennsylvania Rising Star for 2013. Stephen A. Sheller is once again honored for the

2013-02-15   Featured story: “Sheller Family Foundation’s $1.5 million gift to Temple Law will establish Social Justice Center” Stephen and Sandra Sheller, who have spent their respective careers in law and behavioral health

 

2012-12-31  A U.S. Appeals Court ruling that pitted free speech rights versus off-label promotion of pharmaceuticals has raised speculation that 2013 may usher in the sort of aggressive marketing by drug makers that

2012-10-05  The first trial in which evidence was taken in the mass tort litigation over Risperdal, the antipsychotic drug that plaintiffs have claimed causes males to grow breasts, was settled as part of